Immunofunctional Assay of Human Growth Hormone (hGH) in Serum: A Possible Consensus for Quantitative hGH Measurement

CHRISTIAN J. STRASBURGER, ZIDA WU†, CLAUS-DIETER PFLAUM, AND REGINA A. DRESSENDÖRFER‡

Medical Clinic, Innenstadt University Hospital, Ludwig Maximilians University, Munich, Germany

ABSTRACT

Confirmation of the diagnosis of GH deficiency in adults and children involves provocative testing for human (h)GH. Different commercially available immunoassays yield largely discrepant results in the measurement of GH levels in human serum. These discrepancies result in doubtful relevance of cut-off levels proposed for GH provocative testing. We have developed an immunofunctional assay method that allows quantitation of only those GH forms in circulation that possess both binding sites of the hormone for its receptor and thus can initiate a biological signal in target cells. An anti-hGH monoclonal antibody recognizing binding site 2 of hGH is immobilized and used to capture hGH from the serum sample. Biotin-labeled recombinant GH-binding protein in a second incubation step forms a complex with those hGH molecular isoforms that have both binding sites for the receptor. The signal is detected after a short third incubation step with labeled streptavidin. The assay is sensitive (detection range: 0.1-100 pg/mL) and has average inter- and intraassay precisions of 10.3% and 7.3%, respectively. Endogenous GH-binding protein does not interfere with the hGH result; placental lactogen shows no detectable cross-reactivity in this immunofunctional assay. The degree of immunofunctionally active hGH forms in serum samples, calculated by comparison of immunofunctional assay and RIA results, varied between 52-93%. We propose this immunofunctional assay for GH measurement as a new reference method for hGH quantitation in serum. The immunofunctional assay translates only hGH forms into an assay signal that are capable of dimerizing GH receptors and, thus, of initiating a biological effect in target cells. (J Clin Endocrinol Metab 81: 2613–2620, 1996)

THE DETERMINATION of circulating levels of human (h)GH in serum is generally accomplished by the use of commercially available immunoassay kits. The comparative measurement of serum samples by different immunoassay kits results in vastly discrepant results, although most commercial immunoassay kits for GH determination are calibrated against international reference preparations of the hormone (1–3). This heterogeneity of hGH concentrations measured by different immunoassay kits has been attributed to the use of different reference preparations (4), to the heterogeneity of different forms of GH in circulation (5, 6), the epitope specificity of the antibodies employed (7), and differences in standard matrix (8).

The diagnostic procedures in the evaluation of suspected GH deficiency in childhood (9, 10) and recently also in adult patients (11) involve GH measurement after provocative tests. The results obtained by these measurements have profound effects on establishment of the diagnosis and represent the key criteria for reimbursement of the GH replacement therapy costs. Although recommendations exist concerning the provocative testing procedures for the diagnosis of GH deficiency, and cut-off levels have been proposed below which the peak GH levels after provocative tests should be, no consensus has been achieved or proposed for the biochemical procedure of GH measurement itself.

The essential information required by blood sampling for GH determination is the amount of biologically active, functional GH in the circulation at the time of blood sampling. The answer commonly provided by the analytical results, in contrast, represents a quantitation of immunoreactive GH molecular forms in the sample, to which variants, fragments, and aggregates of GH (6) contribute to different extents depending on the epitope specificity of the antibodies employed in the assay (1, 12).

hGH has been shown to induce dimerization of its receptor as the initial step of signal transduction in target cells (13), which leads to phosphorylation of the intracellular domain of the hGH receptor and receptor-associated proteins (14). This process initiates the signal transduction cascade involving JAK2 kinase and STAT (Signal Transduction and Activation of Transcription) proteins (15, 16). The x-ray crystallography structure of a complex formed by one molecule of GH and two GH receptor ecto domains was resolved (17), and the epitopes of the hGH molecule interacting with either receptor molecule have been characterized. The GH molecule sequentially binds to a first receptor molecule with a large contact surface area involving a total of 31 amino acid side-chains (10) of the C-terminal part of the fourth helix bundle, parts of the random coil sequence between helix 1 and helix 2, and parts of helix 1 (13, 19). Consecutively, this 1:1 complex associates a second receptor molecule via binding site 2 of hGH, which represents a much smaller surface...
area on the N-terminal random coil sequence, the beginning of helix 1 and C-terminal parts of helix 3 of the hGH molecule (13).

We have sought to identify monoclonal antibodies (mAbs) specific for both binding domains on the hGH molecule that interact with the receptor molecules and attempted to design an immunoassay procedure more closely reflecting in its results the biologically active proportion of GH in a given serum sample (7). As the epitope recognized by mAbs generally spans over 3–10 amino acid residues (20), no single mAb could be identified representatively binding to the 31 amino acid side-chains involved in interaction on binding site 1 with the receptor (18).

This article describes our approach to design an immunofunctional assay (IFA) for hGH in which only those molecular forms of hGH in the sample to be analyzed translate into an assay signal that is also capable of inducing a receptor dimerization and thereby initiating the signal transduction process on target cells. The IFA is based on the interaction of GH with an immobilized mAb specific for binding site 2 of the hormone and with biotin-labeled recombinant hGH (rhGH)-binding protein (hGHBP), which represents the full-length GH receptor ecto domain.

Materials and Methods

Reagents

Twenty-two-kilodalton rhGH, 20-kDa rhGH, and rhGH dimers were provided by Eli Lilly Co. (Indianapolis, IN). The recombinant reference preparation 88/624 of hGH was obtained from NIBSC (Hartfordshire, UK). Defined fragments of hGH derived from enzymatic or chemical cleavage were kindly donated by Dr. Jack Kostyo (Ann Arbor, MI). Recombinant mutants of hGH lacking the first 7 or 13 amino acid residues, respectively, were gifts from Dr. Tikva Vogel, Biotechnology General (Netziona, Israel). A recombinant variant of hGH in which the C-terminal 9 of 13 amino acids that are heterologous between pituitary hGH and placental GH are mutated to the placental variant with the remainder of the sequence according to the pituitary hGH was a gift from Dr. Par Gellerfors, Kabi Pharmacia (Stockholm, Sweden). Pituitary-derived 22-kDa hGH (AFP-4793B), 20-kDa hGH (AFP-4286B), and polyclonal anti-GH serum from rabbit (AFP-Cl1981A) were gifts from Dr. A. F. Parlow, NIDDK, Harbor-University of California-Los Angeles Medical Center (Torrance, CA). Full-length rhGH receptor ecto domain (amino acids 1–246) was expressed in Escherichia coli by Dr. G. Crivi, Soarle-Monsanto (St. Louis, MO) and extracted and refolded from inclusion bodies by Dr. A. Gertler (Rehovot, Israel). Human placental lactogen (hPL) was purchased from Sigma (Deisenhofen, Germany), and sheep serum was obtained from Paa Biologics (Marburg, Germany). All other reagents were of analytical grade.

mAbs to hGH were produced by the myeloma technique (21) and propagated in protein-free medium (PFHM II, Life Technologies, Eggenstein, Germany). Anti-hGH mAb 7B11 is IgG subtype 1 and has an affinity of 3 × 10^10 L/mol for 22-kDa hGH.

Biotinylation of rhGH and rhGHBP

Biotin-ε-amidocaproyl-γ-butyryl-N-hydroxy succinimide ester was added in a 20-fold molecular excess to either rhGH or rhGHBP following the protocols described previously (22). The reaction mixtures were left for 2 h at ambient temperature and then applied to a Superdex 30 fast protein liquid chromatography column for separation of labeled protein and uncoupled biotin. The biotinylated proteins were stored in 0.2 mmol/L Tris-HCl buffer, pH 7.4, containing 1% BSA in aliquots at –70°C.

End-point detection

Using biotin as a primary probe throughout, the microtiter plates with an immobilized reaction partner and a biotinylated assay component were washed three times with 0.3 mL wash buffer (50 mmol/L Na₂HPO₄, 2% Tween-40, and 0.1% NaNO₂, pH 7.5) and then incubated for 30 min with 10 ng/well europium-labeled streptavidin (Wallac, Turku, Finland) in assay buffer (50 mmol/L Tris-(hydroxymethyl)-aminomethane, 9 g/L NaCl, 0.5 g/L NaNO₂, 0.1 g/L Tween-40, 5 g/L BSA, 0.5 g/L bovine y-globulin, and 20 μmol/L diethylenetriaminepenta acetic acid, pH 7.75). After a 6-fold wash step, the microtiter plates were filled with 0.2 mL enhancement solution (Wallac) to transchelate europium into a highly fluorescent complex. After 5–15 min of agitation on a horizontal shaker, the plate was placed into a Delfia 1232 time-resolved fluorometer to read the signal.

Identification of epitopes recognized by anti-hGH mAbs

More than 40 mAbs have been produced in our laboratory by immunization of BALB/c mice with recombinant 22-kDa GH in addition to anti-hGH-mAbs, previously reported (23). Antibodies were selected to have affinities (Kₐ) for hGH of 10⁸ L/mol or more. The epitope specificities of the anti-hGH mAbs were characterized by performing comparative displacement experiments in which the respective anti-bodies were immobilized to polystyrene surfaces, and the 50% intercept for displacement of biotin-labeled hGH by 22-kDa GH was compared to the 50% intercept of hGH fragments and hGH variants. By analysis of the cross-reactivity of a given monoclonal antibody with these hGH-related forms and projection of the structural alterations in the hGH variants or fragments onto the structural model of the 22-kDa hGH molecule derived from x-ray crystallography analysis (17, 24), the respective epitopes were deduced.

hGH IFA assay standards and patient samples

hGH calibrators containing pituitary-derived hGH in sheep serum were purchased from Medgenix (Fleurus, Belgium). Twenty-two-kilodalton rhGH reference preparation 88/624, containing 2 ng/ampule, was dissolved and diluted in sheep serum or a pool of human serum previously shown to contain less than 0.1 μg/L hGH, as measured by in-house sandwich immunoassay.

Patient sera were obtained after written informed consent from patients with postoperative hypopituitarism undergoing provocative testing for hGH secretion and under GH replacement therapy as well as from patients with active acromegaly undergoing treatment with somatostatin analogs as well as from sera sent into the pituitary hormone laboratory of our university hospital for routine hGH measurement.

Reference hGH immunoassay

A competitive polyclonal RIA was performed by use of the polyclonal antibody provided by the NIDDK (anti-hGH-2) raised in rabbit, following the procedure suggested by the NIDDK, but using 125I-labeled recombinant hGH produced by the iodogen method (25) to a specific activity of 82 μCi/μg.

Nb2 cell bioassay for hGH quantification

The Nb2 assays were carried out in the Section of Pediatric Endocrinology at the Universitäts-Kinderklinik (Tubingen, Germany). Nb2 cells 11 cells and anti-hPRL monoclonal antibody 9C3 as ascites fluid were kindly donated by Dr. H. Friessen (Winnipeg, Canada). The cells were expanded in Fischer’s medium with 10% FCS and transferred to Fischer’s medium with 5% horse serum 48 h before assay [method modified after that of Tanaka et al. (26)]. Two × 10⁵ cells were plated in 24-well microtiter plates and grown in the presence of hGH standard of seven concentrations between 0–24.5 μg/L or in human serum in the presence of a 1:8000 dilution of the anti-hPRL antibody 9C3 for 72 h. The standards were calibrated against International Reference Preparation 80/505. The cell number was determined by a Coulter counter (Cobas Minos STE, Hoffman LaRoche, Grenzach, Germany), and the number of cell doublings was calculated. For estimation of the hGH concentrations in the serum samples, the rate of doublings obtained in the serum under
neutralizing conditions of the anti-hPRL antibody was compared to the number of doublings achieved by the standard concentrations of hGH.

**IFA procedure**

Anti-hGH mAb 7B11, which binds to an epitope largely overlapping with binding site 2 of the hGH molecule, was adsorbed to 96-flat bottom microtiter plates (Nunc, Roskilde, Denmark) by incubation of 500 ng mAb 7B11 in 200 μL 50 mmol/L sodium phosphate buffer, pH 9.6. The plates were sealed with a self-adhesive cover film and stored at 4 C for 12 h to 1 month. After aspiration of the coating solution, the plates were washed three times with washing solution.

Twenty-five microliters of standard or sample were pipetted into the wells, followed by 175 μL assay buffer. The plates were incubated at ambient temperature for 3 h on a horizontal shaker. After a 3-fold wash step, 50 ng/well biotinylated rhGHBP were added in 200 μL assay buffer, and the plates were sealed and incubated overnight (12-16 h) at 4 C. After a 3-fold wash step, the plates were incubated with streptavidin-europium and processed as described above. Figure 1 shows the complex of antibinding site 2 antibody mAb 7811 immobilized to the microtiter plate, hGH, and the biotinylated rhGHBP that binds to binding site 1 as well as the streptavidin-europium complex binding to the biotin moiety of this conjugate. The calibration curve was produced by plotting the hGH concentration of standards and the signal from the time-resolved fluorometric end point in a double logarithmic system and using a spline-fit as provided in the Multicalc software package (Wallac).

Concentrations of unknown samples were read by interpolation of the signal obtained on the standard curve.

**Study of interference from endogenous GHBP on hGH IFA results**

To investigate a potential bias produced by endogenous hGHBP on the reading obtained from the hGH IFA, increasing concentrations of rhGHBP were incubated overnight at 4 C with rhGH at concentrations of 1, 4, 14, and 40 μg/L. rhGHBP concentrations between 500–10,000 pmol/L were used. The reagent mixtures were allowed to form complexes and then assayed in the hGH IFA as unknown samples using a standard curve of rhGH in assay buffer.

**Displacement of biotinylated rhGHBP from immobilized hGH by epitope-specific mAbs**

mAb 10A7 (lgG1; K, for 22-kDa hGH, 6 x 10⁵ L/mol) was immobilized on microtiter plates. This antibody was previously identified to bind to an epitope distant from both receptor-binding sites of the hGH molecule. The antibody was loaded with rhGH by incubation of 0.25 ng/well rhGH in assay buffer for 3 h at ambient temperature. After a wash step, 50 ng/well biotinylated rhGHBP in the absence or presence of increasing concentrations of anti-hGH mAb 7B11 binding to binding site 2 of the hGH molecule or of mAb 8B11 binding to binding site 1 of the molecule (K, for 22-kDa hGH, 7 x 10⁵ L/mol) was allowed to incubate overnight at 4 C. We hypothesized that two biotinylated molecules of hGHBP could bind to each molecule of hGH. As binding of hGH receptors to the hGH molecule is of a sequential nature in which first binding site 1 of the hGH molecule has to be loaded to allow binding site 2-mediated association of a second receptor or binding protein molecule, mAb 7B11 should be able to prevent the association with the second rhGHBP molecule at sufficiently high concentrations of the mAb, retaining association of hGH biotinyl-rhGHBP on binding site 1 and thereby 50% of the maximally detectable signal. In contrast, mAb 8B11 prevented association at binding site 1 and, therefore, also abolished the sequential binding of hGHBP to binding site 2 of hGH; therefore, it should be able to displace the entire signal derived from the association of biotinyl rhGHBP with hGH.

**Results**

**Epitope specificity of anti-hGH mAb 7B11**

Cross-reactivity of mAb 7B11 to hGH-related molecules derived from comparison of 50% intercepts in competitive displacement experiments with increasing concentrations of the respective hGH variant or hGH fragment is shown in Table 1. The relative displacing potency of rhGH was set at 100%. Of the hGH fragments tested, mAb 7B11 shows a high degree of cross-reaction with fragment 1–134, representing roughly the first two thirds of the hGH sequence. A minor cross-reaction of 0.84% was detected with the fragment spanning amino acid residues 15–125; the other tested hGH fragments were not recognized by this mAb.

Twenty-two-kilodalton pituitary-derived hGH (AFP-4793B) showed 53.3% binding potency compared to recombinant 22-kDa hGH. Twenty-two-kilodalton hGH (AFP-4286B) derived from pituitary extract exhibited 45.7% cross-reaction, corresponding to 86% displacing potency of pituitary-derived 22-kDa hGH. hPL, which shares 85% amino acid homology with hGH, has only 0.94% cross-reaction with mAb 7B11, indicating that the epitope recognized by this antibody has a high degree of heterology between hPL and 22-kDa hGH.

Neither N-terminally truncated variants lacking the first 7 or 13 amino acid residues showed any cross-reaction with this mAb, indicating that its binding site overlapped or was near to the N-terminus of the hGH molecule. Finally, the hGH-CV variant showed 22.9% relative displacing potency, indicating that the epitope bound by mAb 7B11 might have one amino acid heterology compared to 22-kDa hGH. Figure 2 shows a model of hGH in which the structural deviations from 22-kDa hGH of the des7 hGH molecule and the hGH-CV variant are indicated. The ellipse shows binding site 2, as

| TABLE 1. Cross-reaction of hGH-related molecules and hGH fragments with mAb 7B11 |
|-----------------|-----------------|
| **hGH variants** | **hGH fragments** |
| hGH (22 kDa) | 100.00% | aa | 20–40 | <0.01% |
| rhGH des° | <0.01% | aa | 1–134 | 22.50% |
| rhGH des 1–3 | <0.01% | aa | 15–125 | 0.84% |
| rhGH CV | 22.90% | aa | 95–134 | <0.01% |
| Pituitary hGH | 53.30% | aa | 126–170 | <0.01% |
| Pituitary hGH (20 kDa) | 45.70% | aa | 135–191 | <0.01% |
| hPL | 0.94% | aa | 141–191 | <0.01% |

Wild-type 22-kDa rhGH was used as reference and arbitrarily assigned 100% reactivity. aa, Amino acids.
FIG. 2. Binding epitope of mAb 7B11 projected onto the x-ray crystallographically derived structure of the GH molecule adapted from the report of Abdel-Meguid et al. (24). The filled plus symbols indicate the sites of mutation in the CV variant of rhGH; the full circles indicate the sites of mutation in the des7 variant of rhGH; the ellipse depicts binding site 2 of the hGH molecule's interaction with its receptor (GH-R) according to the report of Cunningham et al. (13); the circle shows the deduced binding epitope of mAb 7B11.

Functional relevance of mAb 7B11 binding to hGH

Twenty-two-kilodalton hGH immobilized via mAb 10A7 binding an epitope distant from both receptor-binding sites of the hGH molecule was loaded with biotin-labeled rhGHBP, and the displacing potencies of increasing concentrations of mAb 7B11 and mAb 8B11 were investigated as described above. mAb 8B11 bound within binding site 1 of the hGH molecule. The experiment shows that mAb 7B11 maximally displaced 50% of the labeled binding protein molecules, in keeping with blocking of binding site 2. In contrast, increasing concentrations of mAb 8B11 hindered the association of hGH with rhGHBP on binding site 1 and, therefore, consecutively also on binding site 2 and displaced all labeled rhGHBP. Fifty percent displacement was achieved at 30 ng mAb 8B11/well. Results are shown in Fig. 3.

Sensitivity and assay range

Figure 4 shows two hGH IFA standard curves obtained by use of pituitary-derived hGH and rhGH (NIBSC 88/624); the mean ± 1 SD of three independent hGH-IFA standard curves run in duplicate are displayed. The rhGH preparation was more potent than the pituitary-derived hGH. The lower detection limit (sensitivity), as defined by the mean ± 3 SD of a 20-fold zero standard determination, was 0.05 μg/L. The standard curve was linear in a double logarithmic plot of signal over hGH doses up to a concentration of at least 50 μg/L.

Assay reproducibility

Within-assay coefficients of variation were determined for three sera in an 18-fold analysis. At concentrations of 0.43, 5.3, and 19.2 μg/L, the within-assay coefficients of variation were 8.5%, 7.3%, and 6.1%, respectively. Between-assay reproducibility was analyzed by measurements of the same sera in eight independent assays. The respective between-assay coefficients of variation were 12.8%, 9.4%, and 7.9%.

Interference of endogenous hGHBP with the hGH IFA

Fixed concentrations of hGH were preincubated with increasing concentrations of rhGHBP. One microgram per l.
hGH, corresponding to a 45.5 pmol/L concentration, showed the highest susceptibility to interference from endogenous hGHBP. At 2000 pmol/L rhGHBP, the detected concentration of hGH was 97%; at 5000 pmol/L rhGHBP, it was reduced to 56%. Higher concentrations of hGH were less prone to interference. The results of this experiment are shown in Fig. 5. As the physiological concentration of hGHBP in serum samples is approximately 1000 pmol/L (range, 56–1187 pmol/L) (27), no significant interference was expected from endogenous hGHBP concentrations in hGH results obtained by the IFA following this protocol.

**Linearity and recovery**

The linearity of the hGH IFA was evaluated by dilution of serum samples in sheep serum. The results obtained from the IFA were compared to the calculated results. The measured results were within a range of 89–104% of those expected, with a mean of 97.5%. The detailed linearity results are shown in Table 2.

Recovery was evaluated by mixing equal volumes of different sera with rhGH1 calibrators in sheep serum and assaying these as unknowns. The measured results were within 94.7% and 111.7% of those expected, with a mean ± SD of 100.5 ± 7.1%.

**Specificity of the assay**

hPL and 20-kDa hGH, as well as hGH dimers were serially diluted in sheep serum and measured as unknowns in the hGH IFA. Cross-reaction of hPL in the hGH IFA was below 0.001%; 10 mg/L hPL gave no detectable signal. Twenty-kilodalton rhGH showed a relative potency of 0.16% compared to 22-kDa hGH; the dose-response curve was linear in the detectable range between 200-1000 μg/L. Dimers had a relative potency of 111.6%. These specificity data indicate that hPL, which may circulate in extremely high levels during pregnancy, will not interfere in the assay.

**Comparison of hGH IFA with polyclonal hGH RIA**

We decided to compare the hGH-IFA to the polyclonal competitive RIA because the latter method is the most widely applied technique for hGH measurement worldwide and is assumed to yield comparable results between different laboratories. When comparing the results from 128 serum samples from different patients between the hGH IFA and the RIA, both using rhGH1 as the standard, the IFA yielded, on the average, 73.2% of the concentration determined by the RIA (Fig. 6A). This result indicates that serum samples, on the average, contain 27% of molecular forms of hGH that are recognized by RIA, but do not express both binding sites 1 and 2 as measured in the IFA. When replacing the standard used in the RIA by pituitary-derived hGH, as most commonly used throughout, and comparing the results to those from the IFA calibrated again by rhGH, the IFA detects, on the average, 30% of the RIA result (Fig. 6B). The major contribution to this heterology, as deduced from comparing Fig. 6, A and B, is contributed by the heterology of standards; the remainder is determined by the existence of bioinactive hGH forms. The scatter of individual samples around the regression line in the latter regression analysis is reflected by a correlation coefficient of $r^2 = 0.869$, indicating that the degree of bioinactive hGH1 forms in circulation differs between individuals. On an individual basis, the degree of immunofunctionally active hGH forms in serum samples, as calculated by comparison of IFA and RIA results from assays both using rhGH as calibrators (Fig. 6A), varied between 52–93%.

**Comparison of hGH IFA with Nb2 cell bioassay**

Eighteen sera collected for GH determination in the Section of Pediatric Endocrinology at the Universitäts-Kinderklinik (Tubingen, Germany) were selected to cover a range between 1.0–25.8 μg/L by RIA. These sera were analyzed additionally in the Nb2 cell assay and by IFA. The correlation between RIA and Nb2 cell assay, both calibrated against pituitary-derived hGH IRP 80/505, was $r^2 = 0.84$, with a regression line equation of $y_{(RIA)} = 0.39 + 0.89x_{(RIA)}$. IFA results, derived from calibration with recombinant International Reference Preparation 88/624, compared to RIA with $r^2 = 0.88$ and a regression line of $y_{(IFAI)} = 0.04 + 0.54x_{(RIA)}$. The agreement between Nb2 cell assay and the hGH IFA, as shown in Fig. 7, was higher than that of either of the methods compared to RIA, with $r^2 = 0.97$, $y_{(IND2)} = -0.04 + 0.58x_{(IFAI)}$.

---

**Table 2. Linearity of two patient sera determined in the hGH IFA**

<table>
<thead>
<tr>
<th>Serum samples</th>
<th>Measured (μg/L)</th>
<th>Expected (μg/L)</th>
<th>% of expected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum 1, direct</td>
<td>4.51</td>
<td>2.25</td>
<td>104.2</td>
</tr>
<tr>
<td>1:2</td>
<td>3.35</td>
<td>2.25</td>
<td>104.2</td>
</tr>
<tr>
<td>1:4</td>
<td>1.11</td>
<td>1.13</td>
<td>98.4</td>
</tr>
<tr>
<td>1:8</td>
<td>0.50</td>
<td>0.56</td>
<td>88.7</td>
</tr>
<tr>
<td>1:16</td>
<td>0.29</td>
<td>0.28</td>
<td>102.9</td>
</tr>
<tr>
<td>Serum 2, direct</td>
<td>62.80</td>
<td>31.40</td>
<td>100.6</td>
</tr>
<tr>
<td>1:2</td>
<td>31.60</td>
<td>31.40</td>
<td>100.6</td>
</tr>
<tr>
<td>1:4</td>
<td>14.42</td>
<td>15.70</td>
<td>91.8</td>
</tr>
<tr>
<td>1:8</td>
<td>7.45</td>
<td>7.85</td>
<td>94.9</td>
</tr>
<tr>
<td>1:16</td>
<td>3.87</td>
<td>3.92</td>
<td>98.6</td>
</tr>
</tbody>
</table>

Mean ± SD 97.5 ± 5.4
Clinical application of the hGH IFA

The hGH levels determined in arginine infusion tests conducted for the investigation of suspected GH deficiency in adults are displayed in Fig. 8 for six patients who had previously undergone pituitary surgery for nonfunctioning adenomas and who required replacement therapy with glucocorticoids, T₄, and gonadal steroids. In the same figure, for comparison, the results of arginine-induced GH secretion in two healthy volunteers are displayed (the top upper lanes).

hGH levels were also analyzed by IFA and RIA in acromegalic patients before and in hourly intervals for 8 h after application of a single dose of 100 μg somatostatin (Octreotide, Sandoz, Basel, Switzerland). In patients with residual activity of acromegaly after transphenoidal surgery for somatotropin-producing adenoma, both methods showed the expected decay in GH levels after the drug application to between 30–45% of baseline (data not shown). The ratio between the results measured in the RIA and those determined by IFA did not change significantly during this pharmacokinetic study and was in keeping with the results of the regression analysis shown in Fig. 6.

Discussion

We described the development of an immunofunctional assay for the measurement of GH levels in human blood. In this sandwich-type assay, only those molecular forms of GH that possess both binding sites 1 and 2 for the GH receptor generate an assay signal. This is accomplished by immobilization of a monoclonal antibody binding to binding site 2 of hGH and the use of labeled rhGHBP to bind binding site 1 of the hGH molecule. The use of rhGHBP rather than a second monoclonal antibody to GH is essential for this purpose, because only the structural identity of hGHBP with the GH receptor allows for the accurate monitoring of GH's capability of binding to its receptor. As an epitope recognized by a monoclonal antibody spans over a maximum of 10 amino acid residues (20), a monoclonal antibody could not representatively mimic the interaction of GH with its recep-
The immunofunctional hGH assay is suitable for clinical routine use, as characterized by its working range between 0.1–100 μg hGH/L. We have shown that endogenous GHBP levels in physiological concentrations do not result in significant interference with the hGH results derived from the IFA method. By comparison of results from 128 sera measured in both a competitive polyclonal RIA using the same rhGH reference preparation 88/624 and the IFA, it can be concluded that, on the average, 27% of molecular forms in circulation give rise to a signal in the RIA, but not in the IFA.

From the design of the IFA, we conclude that these 27% of hGH forms in circulation do not possess both binding sites for the receptor and, therefore, would not be able to initiate a signal transduction process at target cells, which is known to require receptor dimerization. When comparing the results obtained by use of the IFA and rhGH as the calibrator to those obtained from polyclonal RIA calibrated by use of pituitary hGH, the IFA results were, on the average, only 30% of those from the RIA. The major contribution to this discrepancy, however, is from the different potencies of the calibrators. Direct comparison of RIA results obtained by use of pituitary-derived vs. recombinant calibrator shows a decline in hGH levels to less than 50%. The remainder of the discrepancy between IFA and RIA results accounts for molecular forms not recognized in the IFA, but giving a signal in the RIA.

One possible limitation of the method is its relative overestimation of hGH dimers. After binding to the immobilized mAb 7B11, some of the hGH dimer molecules appear to be capable of binding two labeled hGH receptor ecto domains (hGHBP). An interesting observation was that recombinant 20-kDa hGH showed a dose-response curve parallel to that of 22-kDa hGH, but with a potency of only 0.16% relative to that of 22-kDa hGH. The existing body of literature is controversial as to whether 20-kDa hGH can activate the GH receptor. hPL, the concentration of which in late pregnancy is known to exceed that of GH by a factor of 1000, shares 85% amino acid homology with hGH. At concentrations up to 10 mg/L, hPL does not result in a measurable signal in the hGH IFA.

The use of biotin as a primary probe in the IFA described here allows for versatile end-point determination; the streptavidin-europium conjugate used by us can easily be replaced by a streptavidin-enzyme conjugate for colorimetric end-point determination or any other label attached to streptavidin for which a laboratory is equipped with the respective measurement device. This, in principle, allows for application of the IFA in any endocrine laboratory.

Theoretically, bioassays, although more cumbersome in performance, could provide reliable estimates of biologically active GH levels in serum. The results of hGH determinations by bioassays, however, have to be interpreted with caution, bearing in mind that in these systems the interaction of hGH with receptors of other species, mostly rat GH receptors (28) or rat PRL receptors (29), is monitored. The employment of hGH receptors as expressed on IM9 cells in a competitive binding assay is limited by a lower detection limit of ~2 μg/L (30) due to the rather low affinity of the hGH receptor for its specific ligand, which is on the order of 1 nmol/L.

Liver membrane RRAs lack specificity for hGH (31). The Nb2 cell assay (26), which employs rat lymphoma cells expressing a short form of the rat PRL receptor with a higher affinity for hGH than the hGH receptor with a Kₐ of 1 x 10¹⁰ L/mol appears to be the sole bioassay for hGH that can be performed with tolerable effort in large scale sample series and provides sufficient sensitivity to measure GH levels in the relevant clinical range down to 0.1 μg/L. In Fig. 7, we show very good agreement between the results of the Nb2 cell assay and the hGH IFA in 18 sera. Whether the agreement between the two methods is as high in all instances remains to be investigated by larger series of samples. Potential discrepant results from the Nb2 cell assay and the hGH IFA could be explained by the fact that the Nb2 cell assay studies the interaction of GH with a heterologous receptor and requires blocking of endogenous PRL by the addition of a neutralizing antibody. Independently of these theoretical concerns, the performance and handling of the hGH IFA are substantially easier than those of the Nb2 cell assay because living cells are not used, even though an elegant modified version of the Nb2 cell assay has recently been described in this journal by Uhattam et al. (32).

The high degree of heterogeneity in results of hGH measurements performed by different immunoassays (1) poses a major problem in the standardization of cut-off levels for GH provocative testing. Until now, the highest degree of comparability between results from different laboratories was achieved by application of polyclonal competitive immunoassays. As a consequence of the variations in specificity of the antibodies employed, results differ even between these assays.

As the diagnosis of GH deficiency results in GH replacement therapy, which implies the need for daily sc injections for the patient and substantial cost for the health care system, transparent and standardized diagnostic criteria have to be postulated for the establishment of this diagnosis. Determination of GH levels in provocative tests presently is required for confirmation of the diagnosis and in many countries also for the reimbursement of therapy costs. We, therefore, consider crucial the standardization of the assay procedure and reference preparation used.

For the purpose of harmonization of immunoassay measurements of hGH levels, a consensus has to be achieved with respect to the reference preparation of hGH used for calibration of these methods. Recombinant 22-kDa hGH has recently become available as an international reference preparation and represents a homogeneous, well defined hGH standard. For elimination of heterogeneity in assay results that are attributed to differences in epitope specificities, we propose the IFA method as a possible gold standard for hGH quantitation.

We are currently using the IFA to establish empirical cut-off levels in hGH provocative testing by insulin tolerance test and arginine infusion. Additionally, we intend to address the question of changes in the ratio between immunoassayable and immunofunctionally active forms of hGH in different dynamic tests.
Acknowledgments

We thank Drs. A. Cettler and G. Crivi for providing recombinant hGH BP, Dr. P. Gellers for the hGH-CV variant, Eli Lilly (Indianapolis, IN) for recombinant forms of hGH, Drs. A. F. Parlow and S. Raiti (NIDDK) for pituitary-derived GH preparations and polyclonal anti-hGH antibodies, Dr. J. Kostyo for hGH fragments, and Drs. M. W. Elmlinger and M. B. Ranke (Tubingen, Germany) for performance of Nb2 cell assays and permission to quote collaborative results.

References